Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938139 | 1.00 | TSHR (0.42) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD | |
| SCHEMBL20705369 | 0.86 | — | — | |
| SCHEMBL9423365 | 0.84 | TSHR (0.44) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD | |
| SCHEMBL11616801 | 0.81 | TSHR (0.41) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD | |
| SCHEMBL11616805 | 0.81 | TSHR (0.41) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD | |
| SCHEMBL14231444 | 0.77 | — | — | |
| SCHEMBL27637784 | 0.77 | — | — | |
| SCHEMBL11619739 | 0.76 | TSHR (0.37) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD | |
| SCHEMBL11619730 | 0.76 | TSHR (0.37) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD | |
| SCHEMBL11619736 | 0.76 | TSHR (0.40) | TSHRALDH1A1ZDHHC20ZDHHC2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655305-B1 | PROCESS FOR TELOMERIZATION OF BUTADIENE USING A MONO-ORTHOALKOXY SUBSTITUTED CATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-09-04 | — | — | EP | claimed |
| US-7371909-B2 | Method for producing 1-olefins using palladium carbene compounds | OXENO OLEFINCHEMIE GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| EP-1432666-B1 | METHOD FOR PRODUCING 1-OLEFINS USING PALLADIUM CARBENE COMPOUNDS | OXENO OLEFINCHEMIE GMBH (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040242947-A1 | Method for producing 1-olefins using palladium-carbene compounds | EVONIK DEGUSSA GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1432666-A1 | METHOD FOR PRODUCING 1-OLEFINS USING PALLADIUM CARBENE COMPOUNDS | Oxeno Olefinchemie GmbH (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003031379-A1 | METHOD FOR PRODUCING 1-OLEFINS USING PALLADIUM CARBENE COMPOUNDS | OXENO OLEFINCHEMIE GMBH (DE) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242947-A1 | Method for producing 1-olefins using palladium-carbene compounds | TELO2, PCNA, TTI1 | TSHR 3255/4885ALDH1A1 1419/4885ZDHHC20 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.